REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1120 participants.

Also called NCT07410117

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07410117
  • EU CT 2024-519298-21-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Georgia, Japan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07410117. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-09 (actual); primary completion 2030-01-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Acronym
ROXI-CAT-I
Condition
Cancer-Associated Thrombosis (CAT)
Intervention (Drug)
REGN7508
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07410117
Content hash
b3b2b5331150755583558b16f5f644b73e50ec2a225649ae8d17bf52d3158213